| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $37,432,881 ) (Continued on the next page) |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL163535 | Human Atherogenesis with Underlying Dysfunctional HDL-Free Cholesterol | 001 | 4 | NIH | 4/23/2026 | $22,444 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL163535 | Human Atherogenesis with Underlying Dysfunctional HDL-Free Cholesterol | 000 | 4 | NIH | 3/11/2026 | $710,747 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS140292 | DeepStroke+: An Advanced Mobile AI Diagnostic Tool for Fast and Precise Detection of Acute Strokes in Mobile Stroke Units, Emergency Rooms, and Telestroke Triage | 002 | 2 | NIH | 7/28/2026 | $0 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS140292 | DeepStroke+: An Advanced Mobile AI Diagnostic Tool for Fast and Precise Detection of Acute Strokes in Mobile Stroke Units, Emergency Rooms, and Telestroke Triage | 001 | 2 | NIH | 2/23/2026 | $59,440 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS140292 | DeepStroke+: An Advanced Mobile AI Diagnostic Tool for Fast and Precise Detection of Acute Strokes in Mobile Stroke Units, Emergency Rooms, and Telestroke Triage | 000 | 2 | NIH | 1/19/2026 | $534,966 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL171150 | Sudden Death Risk Assessment and Mechanistic Insights in Arrhythmic Mitral Valve Prolapse Using Cardiac MRI and Circulating Proteomic Biomarkers | 000 | 3 | NIH | 8/5/2026 | $1,833,388 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA294584 | Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment | 001 | 3 | NIH | 6/25/2026 | $1,971,221 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285209 | Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors | 001 | 3 | NIH | 4/16/2026 | $48,987 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285209 | Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors | 000 | 3 | NIH | 1/12/2026 | $440,870 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AA030965 | 4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE) | 000 | 4 | NIH | 8/13/2026 | $403,739 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R61CA278458 | A multiplexed high-throughput platform to report pharmacologic alteration of cancer stem cell membrane potential and cell cycle state | 000 | 3 | NIH | 4/27/2026 | $221,817 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | K23AI185174 | Pathogen and patient determinants of Candida gut colonization in critically ill patients | 000 | 3 | NIH | 6/5/2026 | $194,036 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA284315 | Dual targeting of PI3K and NOS pathways in Metaplastic BreastCancer (MBC) | 000 | 4 | NIH | 6/19/2026 | $654,245 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA282099 | Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells | 000 | 4 | NIH | 7/7/2026 | $473,214 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | T32AI179595 | Antimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT) | 000 | 3 | NIH | 4/21/2026 | $331,510 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL169204 | Metabolism and Epigenetic Regulation are Couples in Transdifferentiation and Vascular Regeneration | 000 | 3 | NIH | 8/21/2026 | $593,514 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285203 | Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy | 000 | 3 | NIH | 5/18/2026 | $472,355 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA283580 | Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity | 000 | 3 | NIH | 6/12/2026 | $610,783 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI181635 | Natural Phenolic Compounds against Oral Candidiasis (OC) | 000 | 3 | NIH | 7/3/2026 | $401,021 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS132123 | Spinal Neuromodulation to Promote Physiologic and Molecular Plasticity in theInjured Spinal Cord | 000 | 4 | NIH | 8/24/2026 | $445,467 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI173138 | Clinical Impact of the Cefazolin Inoculum Effect | 003 | 4 | NIH | 8/26/2026 | $161,779 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI173138 | Clinical Impact of the Cefazolin Inoculum Effect | 002 | 4 | NIH | 8/25/2026 | $54,000 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI173138 | Clinical Impact of the Cefazolin Inoculum Effect | 001 | 4 | NIH | 8/18/2026 | $0 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI173138 | Clinical Impact of the Cefazolin Inoculum Effect | 000 | 4 | NIH | 8/14/2026 | $425,805 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA224275 | Lipid Unsaturation Drives Ovarian Cancer Progression | 000 | 6 | NIH | 6/18/2026 | $641,081 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288884 | Functional roles of mTOR in tumor persistence | 000 | 3 | NIH | 3/19/2026 | $401,087 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA278787 | Role of lipid metabolism in CD8+ T cell ferroptosis | 000 | 4 | NIH | 8/25/2026 | $484,536 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS124813 | Pathogenesis in Segmental Demyelination | 000 | 4 | NIH | 6/25/2026 | $387,106 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA280746 | Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis | 001 | 3 | NIH | 4/16/2026 | $65,879 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA280746 | Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis | 000 | 3 | NIH | 1/27/2026 | $592,923 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS129788 | Relationship of the Human Astrocyte Matrisome with Synaptic Networks | 000 | 5 | NIH | 8/12/2026 | $453,064 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL158703 | Mechanisms driving cardiac dysfunction in Autosomal Dominant Polycystic Kidney Disease | 000 | 5 | NIH | 4/7/2026 | $403,750 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS129720 | “Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response” | 000 | 4 | NIH | 8/26/2026 | $552,142 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R35GM150460 | Landscapes for Cell State Transition Leveraging by Single-Cell Multi-Omics | 000 | 4 | NIH | 8/31/2026 | $403,739 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL168277 | Cardiac Autonomic Activation In Atrial Fibrillation Triggers And Substrate | 001 | 4 | NIH | 4/23/2026 | $24,089 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL168277 | Cardiac Autonomic Activation In Atrial Fibrillation Triggers And Substrate | 000 | 4 | NIH | 3/9/2026 | $762,842 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI167659 | Long-acting multi prevention implant for 2-year contraception and HIV PrEP | 000 | 4 | NIH | 4/17/2026 | $798,886 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL174587 | Advancing Endovascular PAD Treatment: Overcoming Critical Knowledge Gaps with MRI-histology | 000 | 3 | NIH | 5/12/2026 | $704,707 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AI176558 | Regulation of Cell Death in HIV Reservoirs | 000 | 4 | NIH | 2/17/2026 | $593,795 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DK133610 | Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes | 001 | 5 | NIH | 8/31/2026 | $491,493 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DK133610 | Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes | 000 | 5 | NIH | 6/10/2026 | $753,808 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 001 | 4 | NIH | 4/16/2026 | $61,143 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 000 | 4 | NIH | 1/16/2026 | $305,910 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | T32NS126115 | Training in Neural Control of organ Degeneration and Regeneration (NeuralCODR) | 000 | 5 | NIH | 6/23/2026 | $239,867 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 001 | 4 | NIH | 4/16/2026 | $49,214 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 000 | 4 | NIH | 2/11/2026 | $442,928 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA163910 | Targeting ER stress response in B-cell chronic lymphocytic leukemia | 000 | 13 | NIH | 5/7/2026 | $403,750 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288403 | Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy | 000 | 3 | NIH | 5/5/2026 | $589,341 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA272763 | Quantitation of nutrient metabolism in brain tumor patients using advanced 13C isotopomer technology | 000 | 4 | NIH | 8/5/2026 | $364,129 |
|
